

UNAUDITED INTERIM FINANCIAL STATEMENTS ANNOUNCEMENT FOR THE 3 MONTHS FINANCIAL PERIOD (“2Q FY”) ENDED 30 JUNE 2024 AND 6 MONTHS FINANCIAL PERIOD (“HY FY”) ENDED 30 JUNE 2024

This announcement has been prepared by Biolidics Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) and has been reviewed by the Company’s sponsor, Evolve Capital Advisory Private Limited (the “**Sponsor**”), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalyst (“**Catalist Rules**”). This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Jerry Chua (Registered Professional, Evolve Capital Advisory Private Limited), who can be contacted at 138 Robinson Road, Oxley Tower, #13-02, Singapore 068906, telephone: +65 6241 6626.

TABLE OF CONTENTS

	Page
A: Interim consolidated statements of profit or loss and other comprehensive income	2
B: Statements of financial position	3
C: Consolidated statements of cash flows	4
D: Statements of changes in equity	5
E: Selected notes to the financial statements	7
F: Other information required under the Catalist Rules	27

A. INTERIM CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	Note	HY FY2024 S\$'000	HY FY2023 S\$'000	+/(-) %	2Q FY2024 S\$'000	2QFY2023 S\$'000	+/(-) %
Revenue	4	58	176	(67.0)	20	68	(70.6)
Other income	5	75	23	226.1	-	8	n.m.
Changes in inventories		-	(3)	n.m.	-	4	n.m.
Purchases		(28)	(100)	(72.0)	(7)	(22)	(68.2)
Employee benefits expense	6	(624)	(500)	24.8	(356)	(273)	30.4
Depreciation expense	8	(32)	(45)	(28.9)	(14)	(22)	(36.4)
Amortisation expense	8	-	-	n.m.	-	-	n.m.
Research and development expense	8	(1)	(2)	(50.0)	(1)	-	n.m.
Other expenses	8	(571)	(208)	174.5	(202)	(104)	94.2
Finance costs	7	(24)	(64)	(62.5)	(11)	(29)	(62.1)
Loss before tax	8	(1,147)	(723)	58.6	(571)	(370)	54.3
Income tax credit	9	-	-	-	-	-	-
Loss for the period from continuing operations		(1,147)	(723)	58.6	(571)	(370)	54.3
Discontinued operations ^(a,b)							
(Loss) for the period from discontinued operations		(302)	(229)	31.9	(117)	(239)	(51.0)
Loss for the period		(1,449)	(952)	52.2	(688)	(609)	13.0
Other comprehensive gain for the period:							
<i>Items that may be reclassified subsequently to profit or loss</i>							
Effects of translation of foreign operations		68	9	n.m.	-	9	n.m.
Total comprehensive loss for the period		(1,381)	(943)	46.4	(688)	(600)	14.7
Basic and Diluted Loss per share (cents)	10						
- from continuing operations		(0.16)	(0.14)		(0.08)	(0.07)	
- from discontinued operations		(0.04)	(0.04)		(0.02)	(0.04)	
		(0.20)	(0.18)		(0.10)	(0.11)	

n.m. – not meaningful

Notes:

- (a) Financial statements for HY FY2024, HY FY2023, 2Q FY2024 and 2Q FY2023 have been presented after reclassifying Biomedics Laboratory Pte Ltd under discontinued operations after placing it under provisional liquidation on 10 June 2024.
- (b) Discontinued operations is in relation to the creditors voluntary liquidation of Biomedics Laboratory Pte Ltd as announced on 10 June 2024.

B. STATEMENTS OF FINANCIAL POSITION

		Group		Company	
	Note	As at 30/6/24 S\$'000	As at 31/12/23 S\$'000	As at 30/6/24 S\$'000	As at 31/12/23 S\$'000
Non-current assets					
Plant and equipment	11	-	-	-	-
Right-of-use assets	12	82	114	82	114
Intangible assets	13	-	-	-	-
		<u>82</u>	<u>114</u>	<u>82</u>	<u>114</u>
Current assets					
Cash and cash equivalents		150	156	128	127
Trade receivables		8	3	8	3
Prepayments		56	62	56	62
Other receivables		70	61	70	61
Inventories	14	-	-	-	-
Assets held in liquidation		179	286	-	-
		<u>463</u>	<u>568</u>	<u>262</u>	<u>253</u>
Total assets		<u>545</u>	<u>682</u>	<u>344</u>	<u>367</u>
Current liabilities					
Trade payables		16	11	16	8
Other payables		456	436	1,308	437
Contract liabilities		73	90	73	90
Lease liabilities	15	94	137	94	137
Borrowings	15	980	1,080	980	1,080
Provision for reinstatement cost		-	5	-	5
Deferred consideration	16	-	-	-	-
Liabilities held in liquidation		1,114	238	-	-
		<u>2,733</u>	<u>1,997</u>	<u>2,471</u>	<u>1,757</u>
Net current (liabilities)/ assets		<u>(2,270)</u>	<u>(1,429)</u>	<u>(2,209)</u>	<u>(1,504)</u>
Non-current liabilities					
Lease liabilities	15	24	61	24	61
Borrowings	15	176	613	176	613
Provision for reinstatement cost		-	-	-	-
		<u>200</u>	<u>674</u>	<u>200</u>	<u>674</u>
Total liabilities		<u>2,933</u>	<u>2,671</u>	<u>2,671</u>	<u>2,431</u>
Net liabilities		<u>(2,388)</u>	<u>(1,989)</u>	<u>(2,327)</u>	<u>(2,064)</u>
Equity attributable to owners of the Company					
Share capital	18	67,518	66,536	67,518	66,536
Foreign currency translation reserve		90	22	-	-
Accumulated losses		(69,996)	(68,547)	(69,845)	(68,600)
Total equity		<u>(2,388)</u>	<u>(1,989)</u>	<u>(2,327)</u>	<u>(2,064)</u>

C. CONSOLIDATED STATEMENTS OF CASH FLOWS

	Group	
	HY FY2024 S\$'000	HY FY2023 S\$'000
Operating activities		
Loss before income tax:		
From continuing operations	(1,147)	(723)
From discontinued operations	(302)	(229)
	<u>(1,449)</u>	<u>(952)</u>
Adjustments for:		
Amortisation expense	-	-
Depreciation of plant and equipment	4	51
Depreciation of right-of-use assets	65	88
Inventories written off	27	29
Writeback of allowance for inventories	(38)	(51)
(Reversal)/allowance for doubtful debts	(1)	8
Loss/ (gain) from remeasurement of deferred consideration	-	14
Loss on disposal of plant and equipment	-	-
Interest expense on lease liabilities	6	5
Interest expense on borrowings	20	35
Accretion of interest on deferred consideration	-	25
Interest income from fixed deposits	-	(3)
Employee share-based payment – equity settled	-	-
Professional fees – equity settled	50	-
Operating cash flows before movement in working capital	(1,316)	(751)
Trade receivables	25	290
Prepayments	19	33
Other receivables	(10)	118
Inventories (Note A)	18	(134)
Trade payables	5	(77)
Other payables	917	(363)
Contract liabilities	(17)	(92)
Cash flows used in operations	(359)	(976)
Interest received	-	3
Interest paid	(26)	(40)
Net cash used in operating activities	(385)	(1,013)
Investing activities		
Additions to plant and equipment (Note A)	-	-
Additions to intangible assets	-	-
Partial payment of deferred consideration	-	(550)
Net cash used in investing activities	-	(550)
Financing activities		
Proceeds from share issuance	1,004	-
Share issuance expenses	(72)	-
Payment of principal portion of borrowings	(536)	(521)
Payment of principal portion of lease liabilities	(107)	(145)
Net cash used in financing activities	289	(666)
Net decrease in cash and cash equivalents	(96)	(2,229)
Cash and cash equivalents at beginning of the period	183	5,029
Exchange effects on cash and cash equivalents	68	9
Cash and cash equivalents at end of the period	155	2,809

Note A: During HY FY2023 and HY FY2024, the Group transferred inventories to plant and equipment that were loaned out to collaboration partners and customers: -

	HY FY2024 S\$'000	HY FY2023 S\$'000
Transfer of inventories to plant and equipment	-	-

D. STATEMENTS OF CHANGES IN EQUITY

(In S\$'000)

	Share capital	Foreign currency translation reserve	Share-based payment reserve	Accumulated losses	Total equity
Group					
Balance as at 1 January 2024	66,536	22	-	(68,547)	(1,989)
<u>Total comprehensive loss for the period</u>					
Loss for the period	-	-	-	(1,449)	(1,449)
Other comprehensive gain for the period	-	68	-	-	68
Total	-	68	-	(1,449)	(1,381)
<u>Transactions with owners, recognised directly in equity</u>					
Issue of new shares	1,004	-	-	-	1,004
Share issuance expenses	(72)	-	-	-	(72)
Professional fee – equity settled	50	-	-	-	50
Total	982	-	-	-	982
Balance as at 30 June 2024	67,518	90	-	(69,996)	(2,388)
Balance as at 1 January 2023	64,358	13	-	(66,059)	(1,688)
<u>Total comprehensive loss for the period</u>					
Loss for the period	-	-	-	(952)	(952)
Other comprehensive gain for the period	-	9	-	-	9
Total	-	9	-	(952)	(943)
<u>Transactions with owners, recognised directly in equity</u>					
Employee share-based payment – equity settled	611	-	-	-	611
Professional fees – equity settled	-	-	424	-	424
Reclassification upon issuance of shares	424	-	(424)	-	-
Total	1,035	-	-	-	1,035
Balance as at 30 June 2023	65,393	22	-	(67,011)	(1,596)

D. STATEMENTS OF CHANGES IN EQUITY (cont'd)

(In S\$'000)	Share capital	Share-based payment reserve	Accumulated losses	Total equity
Company				
Balance as at 1 January 2024	66,536	-	(68,600)	(2,064)
Loss for the period, representing total comprehensive loss for the period	-	-	(1,245)	(1,245)
Total	-	-	(1,245)	(1,245)
<u>Transactions with owners, recognised directly in equity</u>				
Issue of new shares	1,004	-	-	1,004
Share issuance expenses	(72)	-	-	(72)
Professional fee – equity settled	50	-	-	50
Total	982	-	-	982
Balance as at 30 June 2024	67,518	-	(69,845)	(2,327)
Balance as at 1 January 2023	64,358	-	(66,077)	(1,719)
Loss for the period, representing total comprehensive loss for the period	-	-	(948)	(948)
Total	-	-	(948)	(948)
<u>Transactions with owners, recognised directly in equity</u>				
Issue of new shares	611	-	-	611
Employee share-based payment – equity settled	-	424	-	424
Reclassification upon issuance of shares	424	(424)	-	-
Total	1,035	-	-	1,035
Balance as at 30 June 2023	65,393	-	(67,025)	(1,632)

E. SELECTED NOTES TO THE FINANCIAL STATEMENTS

1. Corporate information

Biolidics Limited (Registration No. 200913076M) is a limited liability company incorporated and domiciled in Singapore. The Company is listed on the Catalist of SGX-ST.

The condensed interim financial statements for HY FY2024 comprise the Company and its subsidiaries (collectively, the “**Group**”).

The principal activities of the Group and the Company are those relating to:

- (a) technology development, technology transfer, marketing, sale and distribution of biomedical technology, life and medicine science related products and services;
- (b) provision of laboratory services; and
- (c) investment holding.

Please note that on 10 June 2024, the Group has announced that Biomedics Laboratory Pte. Ltd. which provides laboratory services was being placed under creditors’ voluntary liquidation.

2. Basis of preparation

The condensed interim financial statements for 2Q FY2024 and HY FY2024 have been prepared in accordance with Singapore Financial Reporting Standards (International) (“**SFRS(I)**”) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last audited financial statements for the year ended 31 December 2023 (“**FY2023**”).

The condensed interim financial statements are presented in Singapore Dollars which is the Company’s functional currency. All financial information presented in Singapore Dollars have been rounded to the nearest thousand, unless otherwise stated.

Material Uncertainty Related to Going Concern

The Group had recorded a net loss of approximately S\$1.45 million and a net operating cash outflow of approximately S\$0.39 million for HY FY2024. As at 30 June 2024, the Group and the Company was in a net equity deficit position of approximately S\$2.39 million and S\$2.33 million respectively, and a negative working capital position of approximately S\$2.27 million and S\$2.21 million respectively. These conditions indicate that a material uncertainty exists that may cast significant doubt on the Group’s ability to continue as a going concern.

The Company had on 28 February 2023, entered into a partial settlement deed (“**Partial Settlement Deed**”) with Clearbridge BSA Pte Ltd (“**CBSA**”) to partially settle approximately S\$1.16 million (“**Partial Settlement Sum**”) of the deferred consideration (“**Deferred Consideration**”) (Note 16) owing by the Company to CBSA in connection with the purchase of the entire issued and paid-up share capital of Biomedics Laboratory Pte. Ltd., of which S\$0.55 million of the Partial Settlement Sum (“**Cash Settlement Sum**”) was settled by way of cash and approximately S\$0.61 million of the Partial Settlement Sum satisfied by way of issuance of 37,500,000 new ordinary shares in the issued share capital of the Company

(“**Consideration Shares**”) at an issue price of S\$0.0163 for each Consideration Share to CBSA. The payment of the Cash Settlement Sum and the issuance of the Consideration Shares to CBSA were completed on 20 March 2023.

On 21 November 2023, the Company entered into a subscription agreement with Mr. Zhu Hua, on the share subscription of 98,500,000 new ordinary shares in the issued share capital of the Company at an issue price of S\$0.0119 per subscription share, to raise gross proceeds of approximately S\$1.17 million. The shares were issued on 21 November 2023 and the Company utilised the net proceeds from the share subscription and its cash to fully repay the Deferred Consideration.

On 21 December 2023, the Company entered into a subscription agreement with Mr. Zhou Chao, on the share subscription of 83,000,000 new ordinary shares in the issued share capital of the Company at an issue price of S\$0.0121 per subscription share, to raise gross proceeds of approximately S\$1.04 million. The Company utilised the net proceeds of approximately S\$0.93 million from the share subscription for working capital purposes.

To provide additional and recurrent revenue streams for the Group, with the approval of shareholders in the Extraordinary General Meeting (“**EGM**”) held on 23 February 2024, the Group will be diversifying its business into Multi-Channel Networking, E-Sports and Live-streaming. This will allow the Group to reduce its reliance on the Group’s existing business in cancer, infectious disease and laboratory services.

To support that the financial statements of the Group have been prepared on a going concern basis and to ensure the adequacy of funds required to meet its obligations, working capital and capital commitment needs, the Group has prepared a consolidated cash flow forecast for a 18-month period from 1 July 2024 to 31 December 2025 (“**Cash Flow Forecast**”). In preparing the Cash Flow Forecast, management has taken the following into consideration:

- the challenges faced by the cancer business, particularly the low demand of our ClearCell FX 1 systems;
- the cost cutting measures that the Group has put in place to manage costs;
- the impact from the proposed acquisition of new business as announced on 24 July 2024; and
- the financial support undertaken by Mr. Zhu Hua.

After taking into consideration the Cash Flow Forecast, the Board is of the opinion that the Group and the Company will be able to operate as a going concern and that the use of the going concern assumption in the preparation of the consolidated financial statements of the Group for 1H FY2024 is appropriate.

In the event that Mr. Zhu Hua does not provide, or is unable to provide, sufficient financial support to the Group for its working capital requirements, the Group will look for alternative sources of funding such as equity or debt fundraising through a placement of securities of the Company to investors or other fundraising opportunities to raise the requisite funding for the Group’s working capital requirements. Should the Group fail to raise such alternative funding, the Company and the Group may not be able to operate as a going concern and trading of the Shares may be suspended pursuant to Rule 1303(3) of the Catalyst Rules.

If the going concern assumption is no longer appropriate, adjustments may have to be made to reflect the situation that assets may need to be realised other than in the normal course of business and at amounts which may differ significantly from the amounts at which they are currently recorded in the statements of financial position. In addition, the Group and the Company may have to reclassify non-current assets and liabilities as current assets and liabilities, respectively. Such adjustments have not been made to these financial statements.

2.1 New and amended standards adopted by the Group

The Group has applied the same accounting policies and methods of computation in the preparation of the condensed interim financial statements for HY FY2024 as compared to those applied in the audited financial statements for FY2023 except for the adoption of new or revised SFRS(I) and Interpretations of Singapore Financial Reporting Standards ("**SFRS(I) INT**") that are mandatory for financial years beginning on or after 1 January 2024. The Group has adopted all applicable SFRS(I) and SFRS(I) INT that are mandatory for financial years beginning on or after 1 January 2024. The adoption of these SFRS(I) and SFRS(I) INT has no significant impact on the Group's consolidated financial statements.

2.2 Use of judgements and estimates

The preparation of the Group's consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting period. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in the future periods.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the audited financial statements for FY2023.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is as follows:

- Identification of a cash-generating unit ("**CGU**") - Management identified the Group's cancer business and laboratory services business as the 2 CGUs in the Group, having considered the products and services being sold by the Group and the inter-dependency of the cashflows arising from the products and services provided within a CGU.

The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period are discussed below. The Group based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

- Expected credit losses ("**ECLs**")

The Group uses a provision matrix to calculate ECLs for trade receivables. The provision rates are based on days past due for groupings of various customer segments that have similar loss patterns. The provision matrix is initially based on the Group's historical observed default rates. The Group will calibrate the matrix to adjust historical credit loss experience with forward-looking information. At every reporting date, historical default rates are updated and changes in the forward-looking estimates are analysed. The assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Group's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the

future. As at 30 June 2024, the carrying amount of the Group's trade receivables was approximately S\$0.08 million (31 December 2023: S\$0.03 million).

In determining the loss allowance for amount due from subsidiaries, when measuring ECL, loss given default constitutes a key input in measuring ECL. Loss given default is an estimate of the loss arising on default. It is based on the difference between the contractual cash flows due and those that the lender would expect to receive. As at 30 June 2024, the carrying amount of the Company's receivables due from subsidiaries was approximately S\$Nil (31 December 2023: S\$Nil).

- Impairment assessment of plant and equipment and right-of-use assets

Management has carried out a review and determined that there are indicators of impairment for the Group's plant and equipment and right-of-use assets. These assets belong to the Group's Cancer and Laboratory Services CGUs that also form the respective operating segments. The Group determines the recoverable amount of the assets of the Cancer and Laboratory Services CGUs based on the higher of value-in-use and fair value less cost of disposals. The recoverable amount of these assets as at 31 December 2023 have been determined based on their fair value less cost of disposal. The fair value less cost of disposal of the CGUs' assets as at 31 December 2023 have been estimated by management, with the assistance of external valuers and are categorised in Level 3 of the fair value hierarchy. The valuation techniques, key assumptions and inputs are provided in the table below and the sources of information include the financial forecasts prepared by management, historical information and external data. Significant judgement has been applied by management in determining the adjustment for economic obsolescence. The Group concluded that no impairment loss is to be recognised in HY FY2024.

- Impairment assessment of investment in subsidiaries

Management has carried out a review and determined that there are indicators of impairment of the Company's investments in subsidiaries. The recoverable amount of the investments as at 31 December 2023 has been estimated based on fair value less cost of disposal of the relevant CGU's assets with adjustments to arrive at equity value of the investments. As at 30 June 2024, the carrying amount of the Company's investment in subsidiaries was Nil (31 December 2023: Nil).

3. Seasonal operations

The Group's businesses were not affected significantly by seasonal or cyclical factors during 2Q FY2024 and HY FY2024.

4. Revenue

The Group derives its revenue from the transfer of goods and services over time and at a point in time in the following major revenue streams. This is consistent with the revenue information that is disclosed for each reportable segment under SFRS(I) 8.

Disaggregation of revenue

	Group		Group	
	HY FY2024	HY FY2023	2Q FY2024	2Q FY2023
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Continued Operations:</u>				
Sale of COVID-19 products	-	-	-	-
Sale of devices and consumables	46	164	20	68
Sale of extended warranty services	12	12	-	-
Total from continuing operations	58	176	20	68
<u>Discontinued Operations:</u>				
Rendering of laboratory services	5	1,021	2	45
Total from discontinued operations	5	1,021	2	45
	63	1,197	22	113

Timing of transfer of goods or services

Continued Operations:

At point in time	46	164	20	68
Over time	12	12	-	-
Total from continuing operations	58	176	20	68

Discontinued Operations:

At point in time	5	1,021	2	45
Over time	-	-	-	-
Total from discontinued operations	5	1,021	2	45
	63	1,197	22	113

5. Other income

	Group		Group	
	HY FY2024	HY FY2023	2Q FY2024	2Q FY2023
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Continued Operations:</u>				
Government grants	65	32	-	7
Other interest income	-	-	-	-
Foreign exchange gain/ (loss), net	2	-	-	-
(Loss)/ Gain from remeasurement of deferred consideration	-	(14)	-	-
Others	8	5	-	1
Total from continuing operations	75	23	-	8
<u>Discontinued Operations:</u>				
Government grants	5	6	11	5
Total from discontinued operations	5	6	11	5
	80	29	11	13

6. Employee benefits expense

	Group		Group	
	HY FY2024	HY FY2023	2Q FY2024	2Q FY2023
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Continued Operations:</u>				
Directors' remuneration	89	77	41	18
Salaries and bonuses	492	471	292	229
Employer's contribution to defined contribution plans	43	48	23	26
Share-based reversal – equity settled	-	-	-	-
Reversal of provision for performance bonus	-	(96)	-	-
Total from continuing operations	624	500	356	273
<u>Discontinued Operations:</u>				
Salaries and bonuses	148	328	60	110
Employer's contribution to defined contribution plans	20	46	9	13
Total from discontinued operations	168	374	69	123
	792	874	425	396

7. Finance costs

	Group		Group	
	HY FY2024	HY FY2023	2Q FY2024	2Q FY2023
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Continued Operations:</u>				
Interest expense on borrowings	20	35	9	17
Interest expense on lease liabilities	4	4	2	2
Accretion of interest on deferred consideration	-	25	-	10
Total from continuing operations	24	64	11	29
<u>Discontinued Operations:</u>				
Interest expense on lease liabilities	2	1	-	-
Total from discontinued operations	2	1	-	-
	26	65	11	29

8. Loss before tax

The following items have been included in arriving at loss before tax:

Continued Operations:

	Group		Group	
	HY FY2024	HY FY2023	2Q FY2024	2Q FY2023
	S\$'000	S\$'000	S\$'000	S\$'000
Amortisation of intangible assets	-	-	-	-
Depreciation of plant and equipment	-	6	-	6
Depreciation of right-of-use assets	32	39	-	36
Loss on disposal of plant and equipment	-	-	-	-
Inventories written off	27	26	3	26
Writeback of allowance for inventories	(38)	(51)	(4)	(51)
Provision/ (Writeback) for unconsumed leave	24	49	(65)	49
Rental expenses	19	2	15	1
Travelling expenses	1	4	(2)	2
Professional fees (cash-settled)	285	26	146	94
Professional fees (equity-settled)	50	-	-	--
Sales and marketing expenses	35	22	21	16
Repairs and maintenance	17	12	5	7
Staff training	3	-	-	-
Delivery charges	2	-	-	1

Research and development expense

Research and development expense are incurred for product and service development, research collaboration and testing purposes.

Discontinued Operations:

	Group		Group	
	HY FY2024	HY FY2023	2Q FY2024	2Q FY2023
	S\$'000	S\$'000	S\$'000	S\$'000
Amortisation of intangible assets	-	-	-	-
Depreciation of plant and equipment	4	-	-	-
Depreciation of right-of-use assets	33	-	-	-
Loss on disposal of plant and equipment	-	-	-	-
Inventories written off	-	3	-	3
Writeback of allowance for inventories	-	-	-	-
Provision/ (Writeback) for unconsumed leave	17	-	(10)	-
Rental expenses	1	-	-	-
Travelling expenses	-	1	(1)	1
Professional fees (cash-settled)	14	122	7	62
Professional fees (equity-settled)	-	-	-	-
Sales and marketing expenses	-	-	-	-
Repairs and maintenance	2	3	1	1
Staff training	-	-	-	-
Delivery charges	-	1	-	1

9. Income tax credit

	Group		Group	
	HY FY2024	HY FY2023	2Q FY2024	2Q FY2023
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Continued and Discontinued Operations:</u>				
Current income tax	-	-	-	-
Deferred income tax				
- Origination and reversal of temporary differences	-	-	-	-
Income tax credit recognised in profit or loss	-	-	-	-

10. Loss per share

Basic loss per share is calculated by dividing loss for the period, net of tax, attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the financial period.

Diluted loss per share is calculated by dividing loss for the period, net of tax, attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the financial period plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares.

	Group	
	HY FY2024	HY FY2023
<u>Continued Operations:</u>		
Loss for the period, net of tax, attributable to owners of the Company used in the computations of basic and diluted loss per share (S\$'000)	(1,147)	(723)
Weighted average number of shares for (basic and diluted) loss per share computation ('000)	734,226	532,665
Basic loss per share (cents)	(0.16)	(0.14)
Diluted loss per share (cents)	(0.16)	(0.14)
<u>Discontinued Operations:</u>		
Loss for the period, net of tax, attributable to owners of the Company used in the computations of basic and diluted loss per share (S\$'000)	(302)	(229)
Weighted average number of shares for (basic and diluted) loss per share computation ('000)	734,226	532,665
Basic loss per share (cents)	(0.04)	(0.04)
Diluted loss per share (cents)	(0.04)	(0.04)

11. Plant and equipment

During HY FY2024, the Group acquired plant and equipment amounting to Nil (HY FY2023: Nil) and transferred inventories amounting to Nil (HY FY2023: Nil), that were loaned out to collaboration partners and customers, to plant and equipment.

Impairment assessment of plant and equipment

The Group has carried out impairment assessment for plant and equipment by estimating the recoverable amounts of the respective CGUs of the Group as disclosed in Note 2.2 under Section E - Selected notes to the financial statements of this announcement. Included in the CGUs are plant and equipment and right-of-use assets. Based on the impairment assessment, no impairment charge was required as at 30 June 2024.

12. Right-of-use assets

The Group has lease contracts for office and warehouse premises, laboratory space, and office and laboratory equipment used in its operations. Leases of office premise, laboratory space and warehouse premise generally have lease terms of 1 year or less, while office and laboratory equipment generally have lease terms of 3 to 5 years. The Group's obligations under its leases are secured by the lessor's title to the leased assets. Generally, the Group is restricted from assigning and subleasing the leased assets. There are no lease contracts that include extension or termination options and variable lease payments.

There were additions of right-of-use assets of S\$32,000 during HY FY2024 (HY FY2023: S\$70,000).

Impairment assessment of right-of-use assets

The Group has carried out impairment assessment for right-of-use assets by estimating the recoverable amounts of the respective CGUs of the Group as disclosed in Note 2.2 under Section E - Selected notes to the financial statements of this announcement. Included in the CGUs are plant and equipment, intangible assets and right-of-use assets. Based on the impairment assessment, no impairment charge was required as at 30 June 2024.

13. Intangible assets

Group	Accreditation	Patent rights	Trademark	Total
	S\$'000	S\$'000	S\$'000	S\$'000
Cost:				
At 31 December 2023 and 30 June 2024	3,329	913	92	4,334
Accumulated amortisation and impairment:				
At 31 December 2023 and 30 June 2024	3,329	913	92	4,334
Carrying amount:				
At 31 December 2023 and 30 June 2024	-	-	-	-

Company	Patent rights S\$'000	Trademark S\$'000	Total S\$'000
Cost:			
At 31 December 2023 and 30 June 2024	913	92	1,005
Accumulated amortisation and impairment:			
At 31 December 2023 and 30 June 2024	913	92	1,005
Carrying amount:			
At 31 December 2023 and 30 June 2024	-	-	-

Impairment assessment of intangible assets

The Group has carried out impairment assessment for intangible assets by estimating the recoverable amounts of the respective CGUs of the Group as disclosed in Note 2.2 under Section E - Selected notes to the financial statements of this announcement. Included in the CGUs are plant and equipment, intangible assets and right-of-use assets. Based on the impairment assessment, no impairment charge or reversal of impairment was required as at 30 June 2024.

14. Inventories

	Group		Company	
	As at 30/6/24 S\$'000	As at 31/12/23 S\$'000	As at 30/6/24 S\$'000	As at 31/12/23 S\$'000
Balance sheet:				
Finished goods	-	-	-	-
	-	-	-	-

	Group	
	HY FY2024 S\$'000	HY FY20223 S\$'000
Income statement:		
Inventories recognised as an expense in cost of sales	28	103
Inclusive of the following charge:		
- Writeback of allowance for inventories	(38)	(51)
Inventories recognised as an expense in other expenses		
- Inventories written off	27	29

15. Loans classified as lease liabilities and borrowings

	Group		Company	
	As at 30/6/24	As at 31/12/23	As at 30/6/24	As at 31/12/23
	S\$'000	S\$'000	S\$'000	S\$'000
Amount repayable within one year or on demand				
Secured (Note A)	20	60	20	60
Unsecured	980	1,080	980	1,080
Amount repayable after one year:				
Secured (Note A)	-	-	-	-
Unsecured	176	613	176	613

Note A: Assets pledged as security

The Group's hire purchase loans classified as lease liabilities, which amounted to S\$20,000 as at 30 June 2024 (31 December 2023: S\$60,000), are secured as collateral against the Group's right-of-use assets which have a net carrying amount of Nil as at 30 June 2024 (31 December 2023: Nil).

16. Deferred consideration

The Company had on 28 February 2023 entered into the Partial Settlement Deed with CBSA to partially settle S\$1,161,250 of the Deferred Consideration, of which S\$550,000 of the Partial Settlement Sum was settled by way of cash and the remaining S\$611,250 was satisfied by way of issuance of 37,500,000 Consideration Shares. The payment of the Cash Settlement Sum and the issuance of the Consideration Shares to CBSA were completed on 20 March 2023. The Deferred Consideration was fully repaid on 30 November 2023.

17. Deferred tax liabilities

There is no deferred tax liabilities of the Group arising in the period.

18. Share capital

	Number of shares	Share capital
		S\$'000
As at 31 December 2023	657,626,605	66,536
Issuance of shares pursuant to the Subscription Agreement with Mr. Zhou Chao	83,000,000	932
Issuance of shares pursuant to the Sponsor Agreement with Evolve Capital Advisory Private Limited	4,132,231	50
As at 30 June 2024	<u>744,758,836</u>	<u>67,518</u>

As at 30 June 2023, the Company had up to 42,159,600 new Shares ("**Award Shares**") to be issued to certain employees and a director of the Company subject to the vesting of outstanding Awards granted under the Plan upon the achievement of predetermined performance targets, of which (a) up to 21,079,800 Awards will vest within 2 months from 1 January 2024, and (b) up to 21,079,800 Awards will vest within 2 months from 1 January 2025. The outstanding 42,159,600 Award Shares represent approximately 7.54% of the total number of issued Shares (excluding treasury shares) as at 30 June 2023.

As at 30 June 2024, the Company had up to 21,079,800 Award Shares to be issued to certain employees and a director of the Company subject to the vesting of the Awards, upon the achievement of predetermined performance targets, which will vest within 2 months from 1 January 2025. The outstanding 21,079,800 Award Shares represent approximately 2.83% of the total number of issued Shares (excluding treasury shares) as at 30 June 2024.

Summarised information regarding the number of Award Shares as at 30 June 2024 is as follows:

	As at the beginning of the financial period	Granted during the financial period	Vested during the financial period	Lapsed/ Forfeited during the financial period	As at end of the financial period
<i>To certain employees and a director</i>					
Number of Award Shares	42,159,600	-	-	21,079,800	21,079,800

There were no treasury shares and subsidiary holdings held by the Company as at 30 June 2023 and 30 June 2024.

19. Share-based payment reserve

Share-based payment reserve represents the equity-settled performance shares granted to directors and employees pursuant to the Plan, and equity-settled shares granted to third party individuals as consideration in lieu of fees for their services rendered and in part as performance-based incentives for future performance of such service. Share-based payment expense is recorded over the requisite service period, which is the vesting period.

There was no share-based payment reserve arising in HY FY2024.

20. Net asset value per share

	Group		Company	
	As at 30/6/24	As at 31/12/23	As at 30/6/24	As at 31/12/23
Net (liability) value (S\$'000)	(2,388)	(1,989)	(2,327)	(2,064)
Number of Shares ('000)	744,759	657,627	744,759	657,627
Net (liability) value per share (cents)	(0.32)	(0.30)	(0.31)	(0.31)

21. Related party transactions

There are no material related party transactions apart from those disclosed elsewhere in the financial statements.

22. Segment information

For management purposes and resource allocation, the Group is organised into business operating units based on reports reviewed by the management team that are used to make strategic decisions.

(a) **Cancer**

The cancer segment involves the identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement and the management of global distributorship network and direct customers in the cancer field.

(b) **Infectious diseases**

The infectious diseases segment involves the identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement and the management of global distributorship network and direct customers in the infectious diseases field.

(c) **Laboratory services**

The laboratory services segment involves the business, operation and provision of laboratory services to customers. Please note that the Group had, on 10 June 2024, announced that Biomedics Laboratory Pte. Ltd. which provides laboratory services was being placed under creditors voluntary liquidation.

(d) **Corporate segment**

The corporate segment involves the corporate functions in supporting the operations of the entire Group.

(e) ***New Businesses***

With the approval of shareholders in the Extraordinary General Meeting held on 23 February 2024, the Group will be diversifying its business into Multi-Channel Networking, E-Sports and Live-streaming ("**New Business**"). To date, the Group has not commenced its New Business as it has been assessing the business feasibility and conducting its due diligence on a potential target.

The Group's principal place of business is in Singapore, with its non-current assets located in Singapore.

Segment profit represents the profit earned by each segment without allocation of other gains and losses, distribution and selling expenses, administrative expenses, finance income and finance cost. This is the measure reported to the chief operating decision makers for the purposes of resource allocation and performance assessment.

Segment revenue and results

The following is an analysis of the Group's revenue and results by reportable segment:

	← Continuing Operations →			Discontinued Operations	
HY FY2024	Cancer S\$'000	Infectious diseases S\$'000	Corporate segment S\$'000	Laboratory services S\$'000	Total S\$'000
Revenue:					
External customers	58	-	-	5	63
Inter-segment	-	-	-	-	-
Total revenue	58	-	-	5	63
Segment results:					
Other income	-	-	76	22	98
Employee benefits expense	(18)	-	(606)	(168)	(792)
Depreciation expense	(5)	-	(27)	(37)	(69)
Amortisation expense	-	-	-	-	-
Research and development expense	(1)	-	-	-	(1)
Other expenses	(69)	-	(503)	(110)	(682)
Finance costs					
Segment profit / (loss) before tax	(60)	(3)	(1,084)	(302)	(1,449)
Income tax credit	-	-	-	-	-
Segment profit / (loss) after tax	(60)	(3)	(1,084)	(302)	(1,449)
Assets:					
Additions to non-current assets	-	-	-	-	-

	← Continuing Operations →			Discontinued Operations	
HY FY2023	Cancer S\$'000	Infectious diseases S\$'000	Corporate segment S\$'000	Laboratory services S\$'000	Total S\$'000
Revenue:					
External customers	176	-	-	1,021	1,197
Inter-segment	-	-	-	-	-
Total revenue	176	-	-	1,021	1,197
Segment results:					
Other income	-	-	23	6	29
Employee benefits expense	(25)	(19)	(486)	(344)	(874)
Depreciation expense	(10)	-	(35)	(94)	(139)
Amortisation expense	-	-	-	-	-
Research and development expense	(2)	-	-	-	(2)
Other expenses	24	-	(232)	(342)	(550)
Finance costs	-	-	(64)	(1)	(65)
Segment profit / (loss) before tax	65	(25)	(763)	(229)	(952)
Income tax credit	-	-	-	-	-
Segment profit / (loss) after tax	65	(25)	(763)	(229)	(952)
Assets:					
Additions to non-current assets	-	-	-	-	-

Geographical information

Revenue information based on the geographical location of customers are as follows:

Segment revenue	Continuing Operations				Discontinued Operations	
	Cancer		Infectious diseases		Laboratory services	
	HY FY2024 S\$'000	HY FY2023 S\$'000	HY FY2024 S\$'000	HY FY2023 S\$'000	HY FY2024 S\$'000	HY FY2023 S\$'000
Singapore	-	-	-	-	5	1,020
Japan	2	2	-	-	-	-
China	-	-	-	-	-	-
Europe	11	3	-	-	-	-
Hong Kong	18	21	-	-	-	-
Taiwan	-	-	-	-	-	-
Philippines	-	-	-	-	-	1
Indonesia	-	-	-	-	-	-
Thailand	27	85	-	-	-	-
Malaysia	-	65	-	-	-	-
	58	176	-	-	5	1,021

Information about major customers

Revenue from three (HY FY2023: five) major customers amounted to approximately S\$0.56 million in HY FY2024 (HY FY2023: S\$1.04 million), arising from sales from the cancer (HY FY2023: cancer and laboratory services segments).

	← Continuing Operations →			Discontinued Operations	
2Q FY2024	Cancer S\$'000	Infectious diseases S\$'000	Corporate segment S\$'000	Laboratory services S\$'000	Total S\$'000
Revenue:					
External customers	20	-	-	2	22
Inter-segment	-	-	-	-	-
Total revenue	20	-	-	2	22
Segment results:					
Other income	-	-	1	1	2
Employee benefits expense	-	-	(356)	(68)	(424)
Depreciation expense	-	-	(14)	(18)	(32)
Amortisation expense	-	-	-	-	-
Research and development expense	(1)	-	-	-	(1)
Other expenses	(18)	-	(185)	(28)	(231)
Finance costs	-	-	(10)	(1)	(11)
Segment profit / (loss) before tax	(5)	(1)	(564)	(119)	(689)
Income tax credit	-	-	-	-	-
Segment profit / (loss) after tax	(5)	(1)	(564)	(119)	(689)
Assets:					
Additions to non-current assets	-	-	-	-	-

	← Continuing Operations →			Discontinued Operations	
2Q FY2023	Cancer S\$'000	Infectious diseases S\$'000	Corporate segment S\$'000	Laboratory services S\$'000	Total S\$'000
Revenue:					
External customers	67	-	-	46	113
Inter-segment	-	-	-	-	-
Total revenue	67	-	-	46	113
Segment results:					
Other income	-	-	9	5	14
Employee benefits expense	(12)	(8)	(266)	(110)	(396)
Depreciation expense	(5)	-	(17)	(20)	(42)
Amortisation expense	-	-	-	-	-
Research and development expense	-	-	-	-	-
Other expenses	26	-	(131)	(120)	(225)
Finance costs	-	-	(28)	(1)	(29)
Segment profit / (loss) before tax	58	(8)	(433)	(226)	(609)
Income tax credit	-	-	-	-	-
Segment profit / (loss) after tax	58	(8)	(433)	(226)	(609)
Assets:					
Additions to non-current assets	-	-	-	-	-

Geographical information

Revenue information based on the geographical location of customers are as follows:

Segment revenue	Continuing Operations				Discontinued Operations	
	Cancer		Infectious diseases		Laboratory services	
	2Q FY2024 S\$'000	2Q FY2023 S\$'000	2Q FY2024 S\$'000	2Q FY2023 S\$'000	2Q FY2024 S\$'000	2Q FY2023 S\$'000
Singapore	-	-	-	-	2	45
Japan	2	1	-	-	-	-
China	-	-	-	-	-	-
Europe	3	-	-	-	-	-
Hong Kong	8	2	-	-	-	-
Taiwan	-	-	-	-	-	-
Philippines	-	-	-	-	-	1
Indonesia	-	-	-	-	-	-
Thailand	7	-	-	-	-	-
Malaysia	-	64	-	-	-	-
	20	67	-	-	2	46

Information about major customers

Revenue from three (2Q FY2023: three) major customers amounted to approximately S\$0.2 million in 2Q FY2024 (2Q FY2023: S\$0.10 million), arising from sales from the cancer and laboratory services segments (2Q FY2023: cancer and laboratory services segments).

F. OTHER INFORMATION REQUIRED UNDER THE CATALIST RULES

PART I - INFORMATION REQUIRED FOR QUARTERLY, HALF-YEAR AND FULL YEAR ANNOUNCEMENTS

- 1(a)(i) An income statement and statement of comprehensive income, or a statement of comprehensive income, for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year.**

Please refer to Section A – Interim consolidated statements of profit or loss and other comprehensive income of this announcement.

- 1(a)(ii) Notes to statement of comprehensive income**

Please refer to Notes 4 to 10 under Section E - Selected notes to the financial statements of this announcement.

- 1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.**

Please refer to Section B - Statements of financial position of this announcement.

- 1(b)(ii) Aggregate amount of group's borrowings and debt securities.**

Please refer to Note 15 under Section E - Selected notes to the financial statements of this announcement.

- 1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.**

Please refer to Section C - Consolidated statements of cash flows of this announcement.

- 1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial period.**

Please refer to Section D - Statements of changes in equity of this announcement.

- 1(d)(ii) Details of any changes in the Company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.**

Please refer to Note 18 under Section E - Selected notes to the financial statements of this announcement.

- 1(d)(iii) Total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.**

Please refer to Note 18 under Section E - Selected notes to the financial statements of this announcement.

- 1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.**

Not applicable.

- 1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.**

Not applicable.

- 2 Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.**

The figures have not been audited or reviewed by the auditors of the Company.

- 3 Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of a matter).**

Not applicable.

- 3A Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:**
(a) Updates on the efforts taken to resolve each outstanding audit issue.
(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.
This is not required for any audit issue that is a material uncertainty relating to going concern.

The Company's previous independent auditor, Baker Tilly TFW LLP ("**Baker Tilly**"), had issued a disclaimer of opinion (the "**Disclaimer of Opinion**") in their independent auditor's report dated 1 April 2024 on the audited consolidated financial statements of the Group and the Company for FY2023. The basis for the Disclaimer of Opinion is in relation to (i) the use of the Group's going concern assumption and (ii) the comparative information with respect to impairment assessment of the Group's plant and equipment, right-of-use assets, intangible assets and goodwill (collectively, "**long-lived assets**"), and the Company's investments in, and other receivable due from, a wholly-owned subsidiary or the Company, Biomedics Laboratory Pte Ltd ("**BML**").

(i) Use of the Group's going concern assumption

To improve the financial health and working capital position of the Group, on 21 November 2023, the Company entered into a subscription agreement with Mr. Zhu Hua, on the share subscription of 98,500,000 new ordinary shares in the issued share capital of the Company at an issue price of S\$0.0119 per subscription share, to raise gross proceeds of approximately S\$1.17 million. The Company utilised the net proceeds of approximately S\$1.11 million from the Share Subscription and approximately S\$0.82 million of cash to fully repay the Deferred Consideration.

On 21 December 2023, the Company entered into a subscription agreement with Mr. Zhou Chao, on the share subscription of 83,000,000 new ordinary shares in the issued share capital of the Company at an issue price of S\$0.0121 per subscription share, to raise gross proceeds of approximately S\$1.04 million. The Company will utilise the net proceeds of approximately S\$0.93 million from the share subscription for working capital purposes.

To provide additional and recurrent revenue streams for the Group, with the approval of shareholders in the Extraordinary General Meeting held on 23 February 2024, the Group will be diversifying its business into Multi-Channel Networking, E-Sports and Live-streaming. This will allow the Group to reduce its reliance on the Group's existing business in cancer, infectious disease and laboratory services.

As disclosed under Note 2 under Section E - Selected notes to the financial statements of this announcement, management has prepared the Group's and the Company's financial statements for 2Q FY2024 on the basis that the Group and the Company will be able to carry on as a going concern for at least twelve months from the end of 30 June 2024 based on factors disclosed in that note.

In the event the going concern assumption is no longer appropriate, the financial effects of adjustments to the carrying amounts, and the current and non-current classification of the Group's and Company's assets and liabilities as at 30 June 2024 could be material

and pervasive and the Company is unable to determine the extent of the adjustments that may be required.

- (ii) *Comparative information with respect to Impairment assessment of the Group's plant and equipment, right-of-use assets, intangible assets and goodwill, and the Company's investments in, and other receivable due from, a wholly-owned subsidiary or the Company.*

In FY2021 and FY2022, the Company was audited by Ernst & Young LLP ("**Ernst & Young**"). For FY2022, The Group had recorded total impairment losses of approximately S\$4.04 million on the long-lived assets. The Company also recorded an impairment loss of approximately S\$3.57 million on its investment in BML and expected credit loss ("**ECL**") allowance of approximately S\$2.12 million against the receivable from BML. The depreciation and amortisation expenses relating to the long-lived assets were approximately \$0.76 million and \$0.42 million respectively.

Ernst & Young in their disclaimer of opinion report on the financial statements for FY2022 expressed that they were unable to determine whether any adjustments might have been necessary with respect to the aforementioned impairment losses, ECL, depreciation and amortisation expenses recorded by the Group and the Company, and the related disclosures for the year ended 31 December 2022 as they are unable to obtain sufficient appropriate evidence on the appropriateness of the carrying and recoverable amount of the aforementioned assets as at 31 December 2021 and they issued a disclaimer of opinion on the financial statements FY2021. Consequently, for FY2023, Bakers Tilly were unable to satisfy ourselves in respect of the possible effect of these matters on the comparability of the above-mentioned current figures and the corresponding figures.

Please refer to Notes 2.2, 11, 12, 13 and 14 under Section E - Selected notes to the financial statements of this announcement for further details.

The Board confirms that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

4 Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

Please refer to Note 2.1 under Section E - Selected notes to the financial statements of this announcement.

5 If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

Please refer to Note 2.1 under Section E - Selected notes to the financial statements of this announcement.

6 Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

Please refer to Note 10 under Section E - Selected notes to the financial statements of this announcement.

7 Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares, excluding treasury shares of the issuer at the end of the (a) current period reported on and (b) immediately preceding financial year.

Please refer to Note 20 under Section E - Selected notes to the financial statements of this announcement.

8 A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:
(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and
(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

REVIEW OF THE GROUP'S PERFORMANCE

Continuing Operations

Revenue

Revenue decreased by 67.0% or S\$0.12 million, from S\$0.18 million in HY FY2023 to S\$0.06 million in HY FY2024, due mainly to no revenue generated from the sales of our ClearCell® FX1 system sales in HY FY2024 as compared to S\$0.12 million revenues generated from the sales in previous year.

Revenue decreased by 70.6% or S\$0.05 million, from S\$0.07 million in 2Q FY2023 to S\$0.02 million in 2Q FY2024, due mainly to no revenue generated from the sales of our ClearCell® FX1 system sales in 2Q FY2024 as compared to S\$0.07 million revenues generated from the sales in 2Q FY2023.

Other income

Other income increased by S\$0.05 million or 226.1%, from S\$0.02 million in HY FY2023 to S\$0.07 million in HY FY2024, due mainly to an increase in government grant of S\$0.05 million.

Other income decreased by S\$0.01 million, from S\$0.01 million in 2Q FY2023 to S\$nil in 2Q FY2024, due mainly to a decrease in other miscellaneous income of S\$0.01 million.

Changes in inventories

We recorded no changes in inventories in the closing balance of our inventories in HY FY2024, as compared to a decrease of S\$3,000 in HY FY2023, and also no changes in inventories in the closing balance of our inventories in 2Q2024, as compared to an increase of S\$4,000 in 2Q FY2023. The fluctuations in the balance of our inventories were due mainly to the timing of purchase and sale of inventories.

Purchases

Our purchases decreased by approximately S\$0.07 million or 72.0%, from S\$0.1 million in HY FY2023 to S\$0.03 million in HY FY2024, this is in line with the decrease in revenue rendering from cancer segment during the financial period.

Our purchase decreased by approximately S\$0.02 million or 68.2%, from approximately S\$22,000 in 2Q FY2023 to S\$7,000 in 2Q FY2024, this is in line with the decrease in revenue rendering from cancer segment during the financial period.

Employee benefits expense

Employee benefits expense increased by S\$0.12 million or 24.8%, from S\$0.5 million in HY FY2023 to S\$0.62 million in HY FY2024 and by S\$0.08 million or 30.4% from S\$0.3 million in 2Q FY2023 to S\$0.4 million in 2Q FY2024, this is mainly due to increase in the Headquarters headcount in 2Q FY2024 which fetched higher salaries.

Depreciation expense

Depreciation expense decreased by S\$0.01 million or 28.9%, from S\$0.04 million in HY FY2023 to S\$0.03 million in HY FY2024 and by S\$8,000 or 36.4%, from approximately S\$22,000 in 2Q FY2023 to approximately S\$14,000 2Q FY2023, due to assets being fully depreciated and/or impaired in HY FY2024 and 2Q FY2024.

Other expenses

Other expenses increased by S\$0.36 million or 174.5%, from S\$0.21 million in HY FY2023 to S\$0.57 million in HY FY2024 and by S\$0.1 million or 94.2% from S\$0.1 million in 2Q FY2023 to S\$0.2 million in 2Q FY2024, this is mainly due to higher professional fees (cash and equity settled) of S\$0.31 million.

Finance costs

Finance costs decreased by S\$0.04 million or 62.5%, from S\$0.06 million in HY FY2023 to S\$0.02 million in HY FY2024 and by S\$0.02 million or 62.1%, from S\$0.03 million in 2Q FY2023 to S\$0.01 million in 2Q FY2024, due mainly to lower balances of borrowings and deferred consideration.

Income tax

There was no income tax recognised in HY FY2024 and 2Q FY2024.

Loss for the period

As a result of the foregoing, loss for the period increased by S\$0.4 million or 58.6%, from S\$0.7 million in HY FY2023 to S\$1.1 million in HY FY2024 and by S\$0.2 million or 54.3%, from S\$0.4 million in 2Q FY2023 to S\$0.6 million in 2Q FY2024.

Discontinued Operations

On 4 July 2024, the voluntary liquidation of Biomedics Laboratory Pte Ltd and appointment of a liquidator at an extraordinary general meeting and a meeting of creditors were approved. Loss after tax from discontinued operations of S\$0.3 million and S\$0.1 million for HY FY2024 and 2Q FY2024 respectively were mainly due to lower revenue generated of S\$1.0 million and S\$0.04 million respectively. However, this is partially offset by the decrease in employee benefits cost for both HY FY2024 and 2Q FY2024.

REVIEW OF THE GROUP'S FINANCIAL POSITION

Non-current assets

The Group's non-current assets decreased by 28.1% or S\$0.03 million, from S\$0.11 million as at 31 December 2023 to S\$0.08 million as at 30 June 2024. This was due to a decrease in right-of-use assets of S\$0.03 million, which arose mainly from the depreciation during the period.

Current assets

The Group's current assets decreased by 18.5% or S\$0.1 million, from S\$0.6 million as at 31 December 2023 to S\$0.5 million as at 30 June 2024. This was due mainly to a decrease in assets held in liquidation by S\$0.1 million.

Current liabilities

The Group's current liabilities increased by 36.9% or S\$0.7 million, from S\$2.0 million as at 31 December 2023 to S\$2.7 million as at 30 June 2024. This was mainly due to an increase in the liabilities held in liquidation of S\$0.9 million and an increase in trade and other payables of S\$0.03 million.

Non-current liabilities

The Group's non-current liabilities decreased by 70.3% or S\$0.47 million, from S\$0.7 million as at 31 December 2023 to S\$0.2 million as at 30 June 2024. This was due mainly to a decrease in (i) borrowings of S\$0.44 million comprising the non-current portion of working capital bank loans; and (ii) non-current portion of lease liabilities of S\$0.04 million.

REVIEW OF THE GROUP'S CASH FLOW STATEMENT

Operating cash outflow before movements in working capital amounted to S\$1.31 million in HY FY2024. Net cash generated from working capital amounted to S\$0.96 million due mainly to (i) increase in other payables of S\$0.92 million and (ii) decrease in trade receivables of S\$0.03 million, partially offset by decrease in contract liabilities of S\$0.02 million.

There is no cash used in or generated from investing activities in HY FY2024.

Net cash generated from financing activities in HY FY2024 amounted to S\$0.29 million. This was due mainly to net proceeds from share issuance of S\$0.93 million, partially offset by the payment of S\$0.54 million and S\$0.11 million of the principal portions of borrowings and lease liabilities respectively in HY FY2024.

As a result of the above, there was a net decrease in cash and cash equivalents by S\$0.1 million, from S\$0.2 million as at 31 December 2023 to S\$0.1 million as at 30 June 2024.

9 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable. No forecast or prospect statement has been previously disclosed to shareholders.

10 A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

On 21 November 2023, the Company entered into a subscription agreement with Mr. Zhu Hua, on the share subscription of 98,500,000 new ordinary shares in the issued share capital of the Company at an issue price of S\$0.0119 per subscription share, to raise net proceeds of approximately S\$1.11 million, which was fully utilised to repay the Deferred Consideration. As part of the subscription agreement, Mr. Zhu Hua had undertaken to provide financial support to the Company. To date, Mr. Zhu Hua has provided interest-free shareholders loan to the Company for the purpose of working capital and repayment of bank borrowings.

On 21 December 2023, the Company entered into a subscription agreement with Mr. Zhou Chao, on the share subscription of 83,000,000 new ordinary shares in the issued share capital of the Company at an issue price of S\$0.0121 per subscription share, to raise net proceeds of approximately S\$0.93 million, which was fully utilised for working capital purposes.

To provide additional and recurrent revenue streams for the Group, with the approval of shareholders in the Extraordinary General Meeting held on 23 February 2024, the Group will be diversifying its business into Multi-Channel Networking, E-Sports and Live-streaming. This will allow the Group to reduce its reliance on the Group's existing business in cancer, infectious disease and laboratory services.

On 24 July 2024, the Company announced a proposed acquisition of an entire registered registered capital of Shenzhen Xiaozhao Network Technology Co., Ltd which operates a business promoting games online and offline through various advertising channels. This is consistent with

the Company duly approved new business in the Extraordinary General Meeting held on 23 February 2024.

The Company will continue to provide timely updates to its shareholders should there be any material development affecting the Group's business and operations.

11

Dividend

(a) Whether an interim (final) ordinary dividend has been declared (recommended)

Nil

(b) (i) Amount per share

Nil

(ii) Previous corresponding period

Nil

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be shared).

Not applicable.

(d) Date the dividend is payable

Not applicable.

(e) Date on which Registrable Transfers received by the Company (up to 5pm) will be registered before entitlements to the dividend are determined

Not applicable.

12

If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

No dividend has been declared by the Company as the Group had incurred losses in HY FY2024.

13 If the group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group does not have general mandate from shareholders for interested person transactions.

There were no interested person transactions (excluding transactions less than S\$100,000 and transactions conducted under the IPT Mandate pursuant to Rule 920 of the Catalist Rules) and interested person transactions conducted under the IPT Mandate pursuant to Rule 920 (excluding transactions less than S\$100,000) during HY FY2004.

14 Negative confirmation by the board pursuant to Rule 705(5)

To the best of the knowledge of the board of directors of the Company ("**Board**"), nothing has come to the attention of the Board which may render the unaudited financial results for HY FY2024 of the Group and the Company to be false or misleading in any material aspect.

15 Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1).

The Company confirms that it has procured the undertakings from all of its directors and executive officers as required under Rule 720(1) of Catalist Rules.

16 Use of placement proceeds

Pursuant to the issuance of 83,000,000 placement shares on 11 January 2024, the Company received net proceeds of approximately S\$0.93 million. As at the date of this announcement, the placement proceeds have been utilised as follows:

(S\$'000)	Amount allocated	Amount utilised as at the date of this announcement	Balance
Working capital requirements of the Group ⁽¹⁾	0.93	0.93	0.00
Total	0.93	0.93	0.00

Note:

(1) The amount utilised for working capital requirements of the Group as at the date of this announcement was mainly for operating expenses (which includes administrative expenses, manpower costs, compliance costs, continuing listing expenses and professional fees) of the Group.

17 Disclosure pursuant to Rule 706A of the Catalist Rules

There was no acquisition or sale of shares by the Company during 2Q FY2024 which requires disclosure pursuant to Rule 706A of the Catalist Rules.

ON BEHALF OF THE BOARD

Zhu Hua
Executive Director and Chairman

13 August 2024